Personalis, Inc. (PSNL)

1.3000 -0.0800 (-5.80%) At close: 04:00PM EDT

Personalis, Inc.

6600 Dumbarton Circle
Fremont, CA 94555
United States
650 752 1300
https://www.personalis.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 223

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Christopher M. Hall	President, CEO & Director	963.75k	N/A	1969
Mr. Aaron L. Tachibana	CFO & COO	811k	N/A	1961
Mr. Stephen M. Moore J.D.	Senior VP, Chief Legal Officer & Corporate Secretary	597.98k	N/A	1972
Dr. Richard Chen M.D., M.S.	Executive VP of R&D and Chief Medical Officer	800.6k	N/A	1971
Dr. Russ B. Altman M.D., Ph.D.	Co-Founder and Member of Clinical & Scientific Advisory Board	N/A	N/A	N/A
Dr. Euan A. Ashley DPHIL, FRCP, M.D., Ph.D.	Co-Founder and Member of Clinical & Scientific Advisory Board	N/A	N/A	1971
Dr. Michael P. Snyder Ph.D.	Co-Founder and Member of Clinical & Scientific Advisory Board	N/A	N/A	N/A
Mr. Michael J Fitzpatrick	Vice President of Worldwide Sales	N/A	N/A	N/A
Dr. Christian Haudenschild Ph.D.	Senior Vice President of Genomic Laboratory Operations	N/A	N/A	N/A
Mr. Stephane Mouradian Ph.D.	Senior Vice President of Business Development	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

Corporate Governance

Personalis, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.